Deputy Director, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine
Director, Cancer Prevention Trials Unit
Professor Sasieni is known for his research in medical statistics and cancer epidemiology. He has pioneered the field of monitoring service screening and made discoveries that have modified the practice of cervical screening. In statistics, he is an acknowledged expert in survival analysis with several important publications, and his method for the analysis of genetic association studies is widely used and cited. He was the first to show that the re-launched cervical screening programme in the UK was having an effect on cervical cancer incidence and mortality. His paper on trends in adenocarcinoma of the cervix was the first to highlight the magnitude of the potential epidemic of this cancer. He has provided the most accurate and detailed quantification of the impact of cervical screening. He discovered that cervical screening using cytology is substantially less effective at preventing cervical cancer in young women than it is in older women. Together with colleagues from St Mark’s hospital, he was the first to show that coloscopic surveillance and polypectomy reduced the incidence of colorectal cancer in those with a moderately elevated risk. With Professor Cuzick, he has researched the value of HPV testing in cervical screening. They produced a landmark overview of HPV testing for the HTA and more recently an individual patient overview of HPV testing in primary cervical screening. He has played a leading role in clinical trials of HPV testing both in the UK and in Peru. More recently, Professor Sasieni has become involved in chemoprevention of cancer and he set up, and is director of, the only UK clinical trials unit specializing in cancer screening and prevention.
- Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Statistics in Medicine 2001; 20:935-949.
- Sasieni PD, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357:1490-93.
- Sasieni P. On the expected number of cancer deaths during follow-up of an initially cancer-free cohort. Epidemiology. 2003;14(1):108-10.
- Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK Audit of Screening Histories. British Journal of Cancer 2003;89:88-93.
- Sasieni P, Cuzick J. The UK breast-screening programme should start at age 47 years. Lancet 2003; 362(9379): 246-247.
- Sasieni P, Winnett A. Martingale difference residuals as a diagnostic tool for the Cox model. Biometrika 2003; 90:899-912.
- Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004; 90(9):1784-1786.
- Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year prospective, follow-up study. BMJ 2005; 331(7524): 1047.
- Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006; 118(8): 2048-2055
- Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer. 2007 Aug 15;121(4):796-802.